-
1
-
-
0032820388
-
Sarcomatoid renal carcinoma: The final common dedifferentiation pathway of renal epithelial malignancies
-
Delahunt B: Sarcomatoid renal carcinoma: The final common dedifferentiation pathway of renal epithelial malignancies. Pathology 31:185-190, 1999
-
(1999)
Pathology
, vol.31
, pp. 185-190
-
-
Delahunt, B.1
-
2
-
-
17444372707
-
A review of prognostic pathologic features and algorithms for patients treated surgically for renal cell carcinoma
-
Lohse CM, Cheville JC: A review of prognostic pathologic features and algorithms for patients treated surgically for renal cell carcinoma. Clin Lab Med 25:433-464, 2005
-
(2005)
Clin Lab Med
, vol.25
, pp. 433-464
-
-
Lohse, C.M.1
Cheville, J.C.2
-
3
-
-
0023193247
-
Sarcomatoid renal cell carcinoma: A treatable entity
-
Sella A, Logothetis CJ, Ro JY, et al: Sarcomatoid renal cell carcinoma: A treatable entity. Cancer 60:1313-1318, 1987
-
(1987)
Cancer
, vol.60
, pp. 1313-1318
-
-
Sella, A.1
Logothetis, C.J.2
Ro, J.Y.3
-
4
-
-
33947198698
-
Immunohistochemical expression of hypoxia inducible factor-1alpha and its downstream molecules in sarcomatoid renal cell carcinoma
-
Tickoo SK, Alden D, Olgac S, et al: Immunohistochemical expression of hypoxia inducible factor-1alpha and its downstream molecules in sarcomatoid renal cell carcinoma. J Urol 177:1258-1263, 2007
-
(2007)
J Urol
, vol.177
, pp. 1258-1263
-
-
Tickoo, S.K.1
Alden, D.2
Olgac, S.3
-
5
-
-
33847682904
-
Sarcomatoid differentiation as a prognostic factor for immunotherapy in metastatic renal cell carcinoma
-
Kwak C, Park YH, Jeong CW, et al: Sarcomatoid differentiation as a prognostic factor for immunotherapy in metastatic renal cell carcinoma. J Surg Oncol 95:317-323, 2007
-
(2007)
J Surg Oncol
, vol.95
, pp. 317-323
-
-
Kwak, C.1
Park, Y.H.2
Jeong, C.W.3
-
6
-
-
0036136548
-
Prognostic factors and survival of patients with sarcomatoid renal cell carcinoma
-
Mian BM, Bhadkamkar N, Slaton JW, et al: Prognostic factors and survival of patients with sarcomatoid renal cell carcinoma. J Urol 167:65-70, 2002
-
(2002)
J Urol
, vol.167
, pp. 65-70
-
-
Mian, B.M.1
Bhadkamkar, N.2
Slaton, J.W.3
-
7
-
-
0023099129
-
Sarcomatoid renal cell carcinoma: Clinicopathologic - A study of 42 cases
-
Ro JY, Ayala AG, Sella A, et al: Sarcomatoid renal cell carcinoma: Clinicopathologic - A study of 42 cases. Cancer 59:516-526, 1987
-
(1987)
Cancer
, vol.59
, pp. 516-526
-
-
Ro, J.Y.1
Ayala, A.G.2
Sella, A.3
-
8
-
-
0033014968
-
Sarcomatoid renal cell carcinoma: Biologic behavior, prognosis, and response to combined surgical resection and immunotherapy
-
Cangiano T, Liao J, Naitoh J, et al: Sarcomatoid renal cell carcinoma: Biologic behavior, prognosis, and response to combined surgical resection and immunotherapy. J Clin Oncol 17:523-528, 1999
-
(1999)
J Clin Oncol
, vol.17
, pp. 523-528
-
-
Cangiano, T.1
Liao, J.2
Naitoh, J.3
-
9
-
-
0035116618
-
Sarcomatoid differentiation in renal cell carcinoma: A study of 101 cases
-
de Peralta-Venturina M, Moch H, Amin M, et al: Sarcomatoid differentiation in renal cell carcinoma: A study of 101 cases. Am J Surg Pathol 25:275-284, 2001
-
(2001)
Am J Surg Pathol
, vol.25
, pp. 275-284
-
-
de Peralta-Venturina, M.1
Moch, H.2
Amin, M.3
-
10
-
-
0037377944
-
Review of sarcomatoid renal cell carcinoma with focus on clinical and pathobiological aspects
-
Kuroda N, Toi M, Hiroi M, et al: Review of sarcomatoid renal cell carcinoma with focus on clinical and pathobiological aspects. Histol Histopathol 18:551-555, 2003
-
(2003)
Histol Histopathol
, vol.18
, pp. 551-555
-
-
Kuroda, N.1
Toi, M.2
Hiroi, M.3
-
11
-
-
58249096408
-
The tyrosine kinase receptor c-Kit is overexpressed in sarcomatoid renal carcinomas
-
abstr 1641
-
Tamboli P, Prieto VG, Bekele BN, et al: The tyrosine kinase receptor c-Kit is overexpressed in sarcomatoid renal carcinomas. Proc Am Soc Clin Oncol 22:408a, 2003 (abstr 1641)
-
(2003)
Proc Am Soc Clin Oncol
, vol.22
-
-
Tamboli, P.1
Prieto, V.G.2
Bekele, B.N.3
-
12
-
-
33748919644
-
Biologic significance of fascin expression in clear cell renal cell carcinoma: Systematic analysis of primary and metastatic tumor tissues using a tissue microarray technique
-
Zigeuner R, Droschl N, Tauber V, et al: Biologic significance of fascin expression in clear cell renal cell carcinoma: Systematic analysis of primary and metastatic tumor tissues using a tissue microarray technique. Urology 68:518-522, 2006
-
(2006)
Urology
, vol.68
, pp. 518-522
-
-
Zigeuner, R.1
Droschl, N.2
Tauber, V.3
-
13
-
-
33845585780
-
Characterization of the mTOR pathway in renal cell carcinoma and its use in predicting patient selection for agents targeting this pathway
-
suppl; abstr 4539, 387s
-
Figlin RA, Seligson D, Wu H, et al: Characterization of the mTOR pathway in renal cell carcinoma and its use in predicting patient selection for agents targeting this pathway. J Clin Oncol 23:387s, 2005 (suppl; abstr 4539)
-
(2005)
J Clin Oncol
, vol.23
-
-
Figlin, R.A.1
Seligson, D.2
Wu, H.3
-
14
-
-
0028898538
-
Mutations of the p53 gene and p53 protein overexpression are associated with sarcomatoid transformation in renal cell carcinomas
-
Oda H, Nakatsuru Y, Ishikawa T: Mutations of the p53 gene and p53 protein overexpression are associated with sarcomatoid transformation in renal cell carcinomas. Cancer Res 55:658-662, 1995
-
(1995)
Cancer Res
, vol.55
, pp. 658-662
-
-
Oda, H.1
Nakatsuru, Y.2
Ishikawa, T.3
-
15
-
-
1842529797
-
Sarcomatoid renal cell carcinoma: An examination of underlying histologic subtype and an analysis of associations with patient outcome
-
Cheville JC, Lohse CM, Zincke H, et al: Sarcomatoid renal cell carcinoma: An examination of underlying histologic subtype and an analysis of associations with patient outcome. Am J Surg Pathol 28:435-441, 2004
-
(2004)
Am J Surg Pathol
, vol.28
, pp. 435-441
-
-
Cheville, J.C.1
Lohse, C.M.2
Zincke, H.3
-
16
-
-
0023200226
-
Sarcomatoid carcinoma of the kidney
-
Bertoni F, Ferri C, Benati A, et al: Sarcomatoid carcinoma of the kidney. J Urol 137:25-28, 1987
-
(1987)
J Urol
, vol.137
, pp. 25-28
-
-
Bertoni, F.1
Ferri, C.2
Benati, A.3
-
17
-
-
0028931821
-
Treatment of sarcomatoid renal cell carcinoma: Is there a role for chemotherapy?
-
Culine S, Bekradda M, Terrier-Lacombe MJ, et al: Treatment of sarcomatoid renal cell carcinoma: Is there a role for chemotherapy? Eur Urol 27:138-141, 1995
-
(1995)
Eur Urol
, vol.27
, pp. 138-141
-
-
Culine, S.1
Bekradda, M.2
Terrier-Lacombe, M.J.3
-
18
-
-
0031809054
-
Impact of histology on the treatment outcome of metastatic or recurrent renal cell carcinoma
-
Wu J, Caliendo G, Hu XP, et al: Impact of histology on the treatment outcome of metastatic or recurrent renal cell carcinoma. Med Oncol 15:44-49, 1998
-
(1998)
Med Oncol
, vol.15
, pp. 44-49
-
-
Wu, J.1
Caliendo, G.2
Hu, X.P.3
-
19
-
-
4243490113
-
Phase I Study of Outpatient Interferon-A (IFN), Doxorubicin (DOXO), and Ifosfamide (IFOS) for Patients with Metastatic Sarcomatoid Carcinoma
-
abstr 1371
-
Wood L, Amato R, Daliani D, et al: Phase I Study of Outpatient Interferon-A (IFN), Doxorubicin (DOXO), and Ifosfamide (IFOS) for Patients with Metastatic Sarcomatoid Carcinoma. J Clin Oncol 18:355a, 1999 (abstr 1371)
-
(1999)
J Clin Oncol
, vol.18
-
-
Wood, L.1
Amato, R.2
Daliani, D.3
-
20
-
-
0036719229
-
Doxorubicin and ifosfamide in patients with metastatic sarcomatoid renal cell carcinoma: A phase II study of the Genitourinary Group of the French Federation of Cancer Centers
-
Escudier B, Droz JP, Rolland F, et al: Doxorubicin and ifosfamide in patients with metastatic sarcomatoid renal cell carcinoma: A phase II study of the Genitourinary Group of the French Federation of Cancer Centers. J Urol 168:959-961, 2002
-
(2002)
J Urol
, vol.168
, pp. 959-961
-
-
Escudier, B.1
Droz, J.P.2
Rolland, F.3
-
21
-
-
4844231761
-
Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma
-
Nanus DM, Garino A, Milowsky MI, et al: Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma. Cancer 101:1545-1551, 2004
-
(2004)
Cancer
, vol.101
, pp. 1545-1551
-
-
Nanus, D.M.1
Garino, A.2
Milowsky, M.I.3
-
22
-
-
41049109411
-
A phase I clinical trial of low-dose interferon-alpha-2A, thalidomide plus gemcitabine and capecitabine for patients with progressive metastatic renal cell carcinoma
-
Amato RJ, Khan M: A phase I clinical trial of low-dose interferon-alpha-2A, thalidomide plus gemcitabine and capecitabine for patients with progressive metastatic renal cell carcinoma. Cancer Chemother Pharmacol 61:1069-1073, 2008
-
(2008)
Cancer Chemother Pharmacol
, vol.61
, pp. 1069-1073
-
-
Amato, R.J.1
Khan, M.2
-
24
-
-
0024460781
-
-
Lupera H, Theodore C, Ghosn M, et al: Phase II trial of combination chemotherapy with dacarbazine, cyclophosphamide, cisplatin, doxorubicin, and vindesine (DECAV) in advanced renal cell cancer. Urology 34:281-283, 1989
-
Lupera H, Theodore C, Ghosn M, et al: Phase II trial of combination chemotherapy with dacarbazine, cyclophosphamide, cisplatin, doxorubicin, and vindesine (DECAV) in advanced renal cell cancer. Urology 34:281-283, 1989
-
-
-
-
25
-
-
0035108057
-
Sustained response of sarcomatoid renal-cell carcinoma to MAID chemotherapy: Case report and review of the literature
-
Bangalore N, Bhargava P, Hawkins MJ, et al: Sustained response of sarcomatoid renal-cell carcinoma to MAID chemotherapy: Case report and review of the literature. Ann Oncol 12:271-274, 2001
-
(2001)
Ann Oncol
, vol.12
, pp. 271-274
-
-
Bangalore, N.1
Bhargava, P.2
Hawkins, M.J.3
-
26
-
-
0037998248
-
Active chemotherapy for bone metastasis in sarcomatoid renal cell carcinoma
-
Hoshi S, Satoh M, Ohyama C, et al: Active chemotherapy for bone metastasis in sarcomatoid renal cell carcinoma. Int J Clin Oncol 8:113-117, 2003
-
(2003)
Int J Clin Oncol
, vol.8
, pp. 113-117
-
-
Hoshi, S.1
Satoh, M.2
Ohyama, C.3
-
27
-
-
13444268939
-
Complete response to adriamycin and ifosfamide in a patient with sarcomatoid renal cell carcinoma
-
Rashid MH, Welsh CT, Bissada NK, et al: Complete response to adriamycin and ifosfamide in a patient with sarcomatoid renal cell carcinoma. Am J Clin Oncol 28:107-108, 2005
-
(2005)
Am J Clin Oncol
, vol.28
, pp. 107-108
-
-
Rashid, M.H.1
Welsh, C.T.2
Bissada, N.K.3
-
28
-
-
18844386435
-
Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy
-
Upton MP, Parker RA, Youmans A, et al: Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy. J Immunother 28:488-495, 2005
-
(2005)
J Immunother
, vol.28
, pp. 488-495
-
-
Upton, M.P.1
Parker, R.A.2
Youmans, A.3
-
29
-
-
0042343801
-
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer
-
Yang JC, Haworth L, Sherry RM, et al: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349:427-434, 2003
-
(2003)
N Engl J Med
, vol.349
, pp. 427-434
-
-
Yang, J.C.1
Haworth, L.2
Sherry, R.M.3
-
30
-
-
33846181370
-
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
-
Motzer RJ, Hutson TE, Tomczak P, et al: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115-124, 2007
-
(2007)
N Engl J Med
, vol.356
, pp. 115-124
-
-
Motzer, R.J.1
Hutson, T.E.2
Tomczak, P.3
-
31
-
-
34548315347
-
Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: Survival and biomarker analysis
-
suppl; abstr 5023, 240s
-
Bukowski RM, Eisen T, Szczylik C, et al: Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: Survival and biomarker analysis. J Clin Oncol 25:240s, 2007 (suppl; abstr 5023)
-
(2007)
J Clin Oncol
, vol.25
-
-
Bukowski, R.M.1
Eisen, T.2
Szczylik, C.3
-
32
-
-
34648873387
-
Sunitinib in metastatic renal cell carcinoma (mRCC): Preliminary assessment of toxicity in an expanded access trial with subpopulation analysis
-
suppl; abstr 5010, 237s
-
Gore ME, Porta C, Oudard S, et al: Sunitinib in metastatic renal cell carcinoma (mRCC): Preliminary assessment of toxicity in an expanded access trial with subpopulation analysis. J Clin Oncol 25:237s, 2007 (suppl; abstr 5010)
-
(2007)
J Clin Oncol
, vol.25
-
-
Gore, M.E.1
Porta, C.2
Oudard, S.3
-
33
-
-
34648863567
-
The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial in North America: Safety and efficacy
-
suppl; abstr 5011, 237s
-
Knox JJ, Figlin RA, Stadler WM, et al: The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial in North America: Safety and efficacy. J Clin Oncol 25:237s, 2007 (suppl; abstr 5011)
-
(2007)
J Clin Oncol
, vol.25
-
-
Knox, J.J.1
Figlin, R.A.2
Stadler, W.M.3
-
34
-
-
33744954585
-
Sunitinib in patients with metastatic renal cell carcinoma
-
Motzer RJ, Rini BI, Bukowski RM, et al: Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295:2516-2524, 2006
-
(2006)
JAMA
, vol.295
, pp. 2516-2524
-
-
Motzer, R.J.1
Rini, B.I.2
Bukowski, R.M.3
-
35
-
-
57449097893
-
Sunitinib and bevacizumab in advanced solid tumors: A phase I trial
-
suppl; abstr 3530, 160s
-
Cooney MM, Garcia JA, Elson P, et al: Sunitinib and bevacizumab in advanced solid tumors: A phase I trial. J Clin Oncol 26:160s, 2008 (suppl; abstr 3530)
-
(2008)
J Clin Oncol
, vol.26
-
-
Cooney, M.M.1
Garcia, J.A.2
Elson, P.3
-
36
-
-
33846148701
-
Sorafenib in advanced clear-cell renal-cell carcinoma
-
Escudier B, Eisen T, Stadler WM, et al: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125-134, 2007
-
(2007)
N Engl J Med
, vol.356
, pp. 125-134
-
-
Escudier, B.1
Eisen, T.2
Stadler, W.M.3
-
37
-
-
0034594628
-
New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
-
Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
-
(2000)
J Natl Cancer Inst
, vol.92
, pp. 205-216
-
-
Therasse, P.1
Arbuck, S.G.2
Eisenhauer, E.A.3
-
38
-
-
33645763970
-
WHO classification of the renal tumors of the adults
-
Lopez-Beltran A, Scarpelli M, Montironi R, et al: 2004 WHO classification of the renal tumors of the adults. Eur Urol 49:798-805, 2006
-
(2004)
Eur Urol
, vol.49
, pp. 798-805
-
-
Lopez-Beltran, A.1
Scarpelli, M.2
Montironi, R.3
-
39
-
-
0036138580
-
Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma
-
Motzer RJ, Bacik J, Murphy BA, et al: Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20:289-296, 2002
-
(2002)
J Clin Oncol
, vol.20
, pp. 289-296
-
-
Motzer, R.J.1
Bacik, J.2
Murphy, B.A.3
-
40
-
-
34547108341
-
Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy
-
Choueiri TK, Garcia JA, Elson P, et al: Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer 110:543-550, 2007
-
(2007)
Cancer
, vol.110
, pp. 543-550
-
-
Choueiri, T.K.1
Garcia, J.A.2
Elson, P.3
-
41
-
-
58249124806
-
A phase I study of sunitinib in combination with gemcitabine in advanced renal cell carcinoma and other solid tumors
-
Presented at, San Francisco, CA, February 14-16
-
Michaelson M, Schwarzberg A, Ryan D, et al: A phase I study of sunitinib in combination with gemcitabine in advanced renal cell carcinoma and other solid tumors. Presented at ASCO Genitourinary Cancers Symposium, San Francisco, CA, February 14-16, 2008
-
(2008)
ASCO Genitourinary Cancers Symposium
-
-
Michaelson, M.1
Schwarzberg, A.2
Ryan, D.3
-
42
-
-
56249108812
-
Sorafenib is superior to combination therapy with gemcitabine plus doxorubicin for patients with sarcomatoid renal cell carcinoma
-
Presented at, San Francisco, CA, February 14-16
-
Staehler M, Schöppler G, Haseke N, et al: Sorafenib is superior to combination therapy with gemcitabine plus doxorubicin for patients with sarcomatoid renal cell carcinoma. Presented at ASCO Genitourinary Cancers Symposium, San Francisco, CA, February 14-16, 2008
-
(2008)
ASCO Genitourinary Cancers Symposium
-
-
Staehler, M.1
Schöppler, G.2
Haseke, N.3
|